Humacyte (NASDAQ:HUMA) Cut to Sell at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen downgraded shares of Humacyte (NASDAQ:HUMA – Free Report) from a hold rating to a sell rating in a research note issued to investors on Sunday morning.

A number of other research firms have also issued reports on HUMA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Humacyte in a research note on Monday, December 15th. Benchmark decreased their price target on Humacyte from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. Barclays began coverage on shares of Humacyte in a report on Wednesday, August 27th. They issued an “overweight” rating and a $3.50 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of Humacyte in a research note on Monday, December 1st. Finally, UBS Group reaffirmed a “buy” rating on shares of Humacyte in a report on Monday, December 1st. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.29.

Get Our Latest Research Report on HUMA

Humacyte Stock Up 5.6%

HUMA opened at $1.13 on Friday. The company has a 50 day moving average of $1.37 and a 200 day moving average of $1.78. The company has a market cap of $211.62 million, a PE ratio of -4.91 and a beta of 1.90. Humacyte has a 12 month low of $1.04 and a 12 month high of $5.66. The company has a current ratio of 1.62, a quick ratio of 0.90 and a debt-to-equity ratio of 2.97.

Humacyte (NASDAQ:HUMA – Get Free Report) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. The business had revenue of $0.75 million during the quarter, compared to analysts’ expectations of $0.92 million. On average, sell-side analysts expect that Humacyte will post -1.27 EPS for the current year.

Institutional Investors Weigh In On Humacyte

Hedge funds have recently bought and sold shares of the stock. Heights Capital Management Inc. purchased a new position in Humacyte in the 1st quarter worth approximately $6,863,000. RA Capital Management L.P. bought a new stake in shares of Humacyte during the 1st quarter worth $5,648,000. Marshall Wace LLP grew its position in Humacyte by 5,308.2% in the second quarter. Marshall Wace LLP now owns 2,639,194 shares of the company’s stock worth $5,516,000 after acquiring an additional 2,590,394 shares in the last quarter. CenterBook Partners LP increased its stake in Humacyte by 141.1% in the second quarter. CenterBook Partners LP now owns 3,430,255 shares of the company’s stock valued at $7,169,000 after acquiring an additional 2,007,743 shares during the last quarter. Finally, Woodline Partners LP increased its stake in Humacyte by 38.7% in the first quarter. Woodline Partners LP now owns 3,950,000 shares of the company’s stock valued at $6,735,000 after acquiring an additional 1,101,198 shares during the last quarter. 44.71% of the stock is currently owned by institutional investors.

Humacyte Company Profile

(Get Free Report)

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.

Read More